Mumbai, Maharashtra, India:GlaxoSmithKline Pharmaceuticals Limited announced its financial results for the second quarter ended June 30, 2012. The growth in Net Sales was 16% and Profit After Tax and before Exceptional Items was 12%. The core Pharmaceuticals business grew by 16.3% for the quarter.
The quarter saw a growth across all the business verticals. Dermatology and Vaccines continued to grow strongly. Despite material cost escalations and adverse exchange rate movement, the EBITDA margin was 33% for the quarter.
In the Second quarter, the Company launched Uricostat for Gout treatment. The Company expanded its Oncology portfolio by launching HycamtinTM to fulfil unmet needs for patients with advance cancers and relapsed small cell lung cancer (SCLC).
The company also introduced Volibris (Ambrisentan), a non-sulphonamide class endothelin receptor antagonist (ERA) used to treat pulmonary arterial hypertension (PAH).
During the quarter, a Metered Dose Inhaler (MDI) with dose counter was launched, which will help patients keep a correct count of drug doses taken. This technology has been introduced in Seretide Evohalerή.
Commenting on the performance, Dr. Hasit B. Joshipura, Managing Director, said, “Growth for the quarter was market competitive, with all the segments delivering strong growth.”
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com.
To view the results, please click on the link given below:
Statement of Standalone Unaudited Results for the Quarter and Six Months ended June 30, 2012
Nandini Goswami, General Manager, Corporate Communications, , +91 (22) 24959203